the national news. as luck would have it, we brought you the story for the first time a week ago at this time. it s a story out of new mexico. just tonight as we are getting on the air, there is a major development in that story tonight and it is a shocking one. i imagine given these new developments in the story, this will not be the only place you will be hearing about this over the next several days. all right, what we were able to tell you last week is news of a spate of recent shootings that had targeted the homes and offices of at least a half dozen elected officials in new mexico, all of them members of the democratic party. no one was injured in these shootings. these shootings hit buildings, not people. but they apparently had all been targeted at democratic politicians during december and january. so just over the last few weeks. we first learned of the shootings at five homes and offices belonging to some county commissioners and two state senators and new mexico s
if americans aren t going to get those new booster shots, do we still benefit from the baseline immunity that we got from so many americans getting the first round of shots more than a year ago, or as the virus develops and we don t get additional shots because the country is sick and tired of getting additional boosters, do we run the risk of reverting to the kind of vulnerability that essentially an unvaccinated population would have? more infections of course mean more chances for the virus to mutate and create new variants. as the virus mutates and creates new variants, does that affect the accuracy of our testing technology? does that affect the effect effectiveness of our available treatments? the treatments have been very effective. but right now things like oral anti-virals, paxlovid, those are available and effective. monoclonal antibodies have become obsolete as the virus has developed. what s the status on emerging new treatments? are there fears about some of
the risk of reverting to the kind of vulnerability that essentially an unvaccinated population would have? more infections of course mean more chances for the virus to mutate and create new variants. as the virus mutates and creates new variants, does that affect the accuracy of our testing technology? does that affect the effectiveness of our available treatments? the treatments have been very effective. but right now things like oral anti-virals, paxlovid, those are available and effective. monoclonal antibodies have become obsolete as the virus has developed. what s the status on emerging new treatments? are there fears about some of the existing anti-virals that are working now becoming obsolete in the future as the virus evolves? how s the distribution going for the anti-viral medications that we do have? as we speak, the white house is reportedly discussing ending the formal emergency declaration around covid that s been in effect since 2020. if that is going to end, if we re no